Payment overview · 2025
General Payments
$729.01
20 reported records · 6 companies
Healthcare provider profile · identity verified
Sobha Panicker-Thomas
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · STATEN ISLAND, NY · NPI 1134678022
Verified facts
What the public records show
CMS Open Payments records show Sobha Panicker-Thomas received $729.01 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 77.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $561.31 | 77.0% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.05 | 6.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.39 | 5.7% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $30.24 | 4.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.50 | 3.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.52 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $729.01 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $494.84 | 9 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $66.47 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.39 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 31 |
| Gabapentin | Gabapentin | 137 | 23 |
| Mirtazapine | Mirtazapine | 124 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 31 |
| Eliquis | Apixaban | 106 | 25 |
| Vraylar | Cariprazine Hcl | 100 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 99 | 26 |
| Midodrine Hcl | Midodrine Hcl | 97 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 29 |
| Furosemide | Furosemide | 83 | 20 |
| Levetiracetam | Levetiracetam | 82 | 22 |
| Omeprazole | Omeprazole | 78 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 75 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 75 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 23 |
| Prednisone | Prednisone | 66 | 33 |
| Lactulose | Lactulose | 59 | 18 |
| Metformin Hcl | Metformin Hcl | 58 | 24 |
| Famotidine | Famotidine | 55 | 15 |
| Trazodone Hcl | Trazodone Hcl | 51 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Meropenem | Meropenem | 39 | 11 |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Losartan Potassium | Losartan Potassium | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 11 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Olanzapine | Olanzapine | 31 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Silodosin | Silodosin | 30 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Lisinopril | Lisinopril | 28 | 11 |
| Vancomycin Hcl | Vancomycin Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Clozapine | Clozapine | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Jardiance | Empagliflozin | 17 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl In 5 % Dextrose | 14 | suppressed |
| Austedo Xr | Deutetrabenazine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $729.01 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, GLASSIA, NUCALA, OFEV, REXULTI, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error